Thomas A. Fitzgerald
Chief Financial Officer, Director · Transcode Therapeutics, Inc.
Individual
- 2026
- Sep 11, 2026
- 1
Other insiders active in the same sector
No other insider has filed at Thomas A. Fitzgerald's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Keith S. Manchester - $154.47M in ROIV purchases and sales in the last 12 months
- QVT Financial LP - $147.38M in ROIV purchases and sales in the last 12 months
- Daniel Allen Gold - $147.38M in ROIV purchases and sales in the last 12 months
- ULSE Inc. - $146.25M in ULS purchases and sales in the last 12 months
- Matthew Rabinowitz - $142.97M in NTRA purchases and sales in the last 12 months
- BAIN CAPITAL INVESTORS LLC - $134.38M in KLRA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Thomas A. Fitzgerald?
Thomas A. Fitzgerald is a corporate insider, tracked as Chief Financial Officer, Director of Transcode Therapeutics, Inc. (RNAZ). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Thomas A. Fitzgerald submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.